126 related articles for article (PubMed ID: 21898374)
1. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
Michaelson MD
Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
[No Abstract] [Full Text] [Related]
2. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
3. Sunitinib still fi rst-line therapy for metastatic renal cancer.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e420. PubMed ID: 25328943
[No Abstract] [Full Text] [Related]
4. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
[No Abstract] [Full Text] [Related]
6. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Gschwend JE
Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
[TBL] [Abstract][Full Text] [Related]
7. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
8. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
9. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Oudard S
Anticancer Res; 2010 Dec; 30(12):5223-5. PubMed ID: 21187517
[TBL] [Abstract][Full Text] [Related]
10. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
11. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
Mansueto G; Longo F
Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
[No Abstract] [Full Text] [Related]
12. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
13. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapy - point blank or single shot].
Rübben H
Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
[No Abstract] [Full Text] [Related]
16. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M; Mlineritsch B; Ressler S; Moik M; Kappacher A; Rosenlechner S; Greil R
Oncology; 2011; 80(1-2):34-41. PubMed ID: 21606662
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and everolimus in renal cancer: a rational way forward.
Stadler WM; Phillips G; George DJ; Halabi S; Small E
J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
[No Abstract] [Full Text] [Related]
18. [A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Nakamura M; Yao M; Sano F; Sakata R; Tatenuma T; Makiyama K; Nakaigawa N; Kubota Y
Hinyokika Kiyo; 2013 Aug; 59(8):503-6. PubMed ID: 23995526
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
20. Kidney cancer: SWITCHing inconsequential.
Thoma C
Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
